Diagnostic Imaging Services shares a news story regarding early approval by the Food & Drug Administration (FDA) for promising breast cancer drug. Pfizer Inc.’s drug Ibrance was approved for advanced breast cancer by U.S. regulators more than two months ahead of schedule, letting the drugmaker proceed with one of its most promising new blockbusters. Pfizer estimated Ibrance could be an … Read More